RxDoctor Payments Data

Karen Brown, MD

Vascular & Interventional Radiology · New York, NYNPI 1558349225

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,747 of the $12,515 with a category attached, or 93.9%. Instylla, Inc. accounts for 87.9% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $10,048 and has fallen 97.8% since, to $223 in 2025.

$12,515in general payments, 2019–2025

Across 13 payments — averaging $962.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Instylla, Inc.$11K
  • AstraZeneca$924
  • Boston Scientific$216
  • Galvanize Therapeutics, Inc$140
  • Incyte Corporation$110
  • Cook Medical LLC$83
  • plus $43 from 1 others
$20,737in research payments, 2019–2025

Across 5 payments — averaging $4147.41 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Instylla, Inc.$21K

What the payments were for

  • Consulting fees$11,74794%
  • Food & beverage$7696%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,515 in reported general payments places this provider in the 80th percentile of 306 vascular & interventional radiology providers in New York.

See all vascular & interventional radiology providers in New York

Medicare billing

Part B allowed, 2024
$13,298
Medicare patients
73
Services billed
170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other vascular & interventional radiology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →